Chlorpromazine Haloperidol Apomorphine Ropnirole Spontaneous movement Automated behavior measurement Drug discovery Zebrafish models of human neuropsychiatric diseases offer opportunities to identify novel therapeutic targets and treatments through phenotype-based genetic or chemical modifier screens. In order to develop an assay to detect rescue of zebrafish models of Parkinsonism, we characterized spontaneous zebrafish larval motor behavior from 3 to 9 days post fertilization in a microtiter plate format suitable for screening, and clarified the role of dopaminergic signaling in its regulation. The proportion of time that larvae spent moving increased progressively between 3 and 9 dpf, whereas their active velocity decreased between 5 and 6 dpf as sporadic burst movements gave way to a more mature beat-and-glide pattern. Spontaneous movement varied between larvae and during the course of recordings as a result of intrinsic larval factors including genetic background. Variability decreased with age, such that small differences between groups of larvae exposed to different experimental conditions could be detected robustly by 6 to 7 dpf. Suppression of endogenous dopaminergic signaling by exposure to MPP + , haloperidol or chlorpromazine reduced mean velocity by decreasing the frequency with which spontaneous movements were initiated, but did not alter active velocity. The variability of mean velocity assays could be reduced by analyzing groups of larvae for each data point, yielding acceptable screening window coefficients; the sample size required in each group was determined by the magnitude of the motor phenotype in different models. For chlorpromazine exposure, samples of four larvae allowed robust separation of treated and untreated data points (Z = 0.42), whereas the milder impairment provoked by MPP + necessitated groups of eight larvae in order to provide a useful discovery assay (Z = 0.13). Quantification of spontaneous larval movement offers a simple method to determine functional integrity of motor systems, and may be a useful tool to isolate novel molecular modulators of Parkinsonism phenotypes. Published by Elsevier Inc.
Zebrafish models of human neuropsychiatric diseases offer opportunities to identify novel therapeutic targets and treatments through phenotype-based genetic or chemical modifier screens. In order to develop an assay to detect rescue of zebrafish models of Parkinsonism, we characterized spontaneous zebrafish larval motor behavior from 3 to 9 days post fertilization in a microtiter plate format suitable for screening, and clarified the role of dopaminergic signaling in its regulation. The proportion of time that larvae spent moving increased progressively between 3 and 9 dpf, whereas their active velocity decreased between 5 and 6 dpf as sporadic burst movements gave way to a more mature beat-and-glide pattern. Spontaneous movement varied between larvae and during the course of recordings as a result of intrinsic larval factors including genetic background. Variability decreased with age, such that small differences between groups of larvae exposed to different experimental conditions could be detected robustly by 6 to 7 dpf. Suppression of endogenous dopaminergic signaling by exposure to MPP + , haloperidol or chlorpromazine reduced mean velocity by decreasing the frequency with which spontaneous movements were initiated, but did not alter active velocity. The variability of mean velocity assays could be reduced by analyzing groups of larvae for each data point, yielding acceptable screening window coefficients; the sample size required in each group was determined by the magnitude of the motor phenotype in different models. For chlorpromazine exposure, samples of four larvae allowed robust separation of treated and untreated data points (Z = 0.42), whereas the milder
Introduction
The long-term aim of our work is to develop improved treatments for neurological diseases associated with movement disorders. The zebrafish presents some methodological advantages as a tool to achieve this goal, including the unique applicability of highthroughput screening in a vertebrate model in vivo. Zebrafish larvae can be housed in 96-well plates, allowing libraries of small molecules to be assayed against phenotypes in order to identify compounds with disease-modifying potential (Zon and Peterson, 2005) . Importantly, this can be carried out without making prior assumptions regarding drug targets, which might otherwise limit opportunities for discovery. Consequently, there is much interest in exploiting zebrafish models for the analysis of diseases and possible identification of new treatments. Phylogenetic conservation of many molecular, cellular and neuroanatomical features suggests that the zebrafish CNS presents a suitable biochemical and tissue environment to model human neurological disease, a prediction supported by recent studies showing that genetic or chemical manipulation of zebrafish can Neurobiology of Disease 44 (2011) 9-18 
